Continuing Education on Hematology
The recent years have witnessed major advances in the treatment of benign rare blood disorders such as hemophilia, sickle cell disease (SCD), and cold agglutinin disease (CAD). Moreover, new guidelines have been developed for the diagnosis and management of these blood disorders. Clinicians including hematologists and emergency department physicians need to remain up to date on the various aspects of management of these hematological disorders to diagnose, treat, and manage associated complications. Moreover, access to novel therapies remains challenging due to payer restrictions including step therapy policies. Hematologists and their care team need education on streamlining the prior authorization processes to prevent treatment delays.
Hematology CE/CME Activities
The CME Outfitters Hematology Hub is designed to provide clinicians with the latest clinical practice guidelines, diagnostic strategies and tools, scientific updates on current and emerging therapies, latest guidelines to optimize the management of hematological disorders, and strategies to streamline prior authorization process. In addition, the Hematology Hub also provides patient education tools to empower patients to make informed decisions about their care and to navigate the prior authorization process.
The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward
|
|
The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies. In this CME Outfitters OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond. |
Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC
|
|
Despite the development of investigational and therapeutic options for prostate cancer, a lack of consensus among clinicians regarding patient management in early disease stages remains. Patients with locally advanced or metastatic castration-sensitive prostate cancer should receive androgen deprivation therapy (ADT) after definitive therapy, and it is imperative that clinicians consider luteinizing hormone releasing hormone (LHRH) antagonists in patients with major adverse cardiovascular events (MACE) risk factors. Additionally, must weigh factors that might negatively impact ADT adherence against the choice of ADT. This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies |
Management of Patients with Metastatic Castration-Sensitive Prostrate Cancer
|
|
In this CME Outfitters podcast, expert faculty focus on patient selection criteria for second-generation antiandrogen therapy and the role of molecular testing risk stratification of patients with metastatic CSPC. |
Disease States and Staging of Castration-Sensitive Prostate Cancer
|
|
The first episode of this CME Outfitters podcast series on castration-sensitive prostate cancer (CSPC) will outline the current state of staging in CSPC and clarify the findings of reports detailing the pathology of prostate cancer specimens. |
Real-World Data for Real-World Patients: A Broadened Lens to Informed Decision-Making in Venous Thromboembolism
|
|
This CMEOCast podcast will compare the safety and efficacy of DOACs versus VKAs based on RWD, its methodology, study design, and assessment considerations, and focus on integrating this data into practice to individualize treatment decision-making for patients with VTE. |
Cutting Through Comorbidities: Clearing the Way to Appropriate Anticoagulant Therapy in Patients at Risk for Deep Vein Thrombosis and Pulmonary Embolism
|
|
In this CME Outfitters BriefCase you will meet Walter, a 71-year-old African-American male who presents to his primary care physician’s office with swelling in his right leg. Expert faculty will assess the common comorbidities and discuss applying anticoagulant strategies that reflect randomized controlled trials (RCTs), real-world data, and individual patient characteristics. |
Addressing Disparities in Care: Assessing Patient Characteristics When Determining Next Steps for Anticoagulant Treatment Selection
|
|
The second installment of this CME Outfitters BriefCase series introduces Gordon, a 67-year-old Black man who complains of recent pain and swelling in his right leg, and explores this case with a focus on the impact of racial and ethnic disparities on the care of individuals who are candidates for anticoagulation therapy, and applying patient selection criteria for anticoagulation treatment that minimizes disparities and unconscious bias to optimize patient outcomes. |
Clinician Resources
Hemophilia
- Guidelines For The Management Of Hemophillia 2nd Edition
- Guidelines For Emergency Department Management Of Individuals With Hemophillia And Other Bleeding Disorders
- NHF Position Statement Regarding Standardized Prior Authorization
- HFA Prior Authorization Issue Brief
- HFA Issue Brief: Non-Medical Switching and Step Therapy
Sickle Cell Disease
- Evidence-Based Management of Sickle Cell Disease
- Major Complications of Sickle Cell Disease and Nursing Implications
- Evidence-Based Management of Sickle Cell Disease
- Tips About Sickle Cell Disease
- The Management of Sickle Cell Disease
Cold Agglutinin Disease
Patient Resources
Hemophilia
- What is hemophilia A?
- What is hemophilia B?
- Treatment of hemophilia
- Types of prophylaxis
- What is an inhibitor?
- Who is at risk for developing an inhibitor?
- Treatment for inhibitors
- What types of bleeds are there?
- Preventing bleeding
- Costs and considerations
- Video: Prior Authorization in Hemophilia
Sickle Cell Disease
Discover additional accredited CME/CE activities and patient resources on the Virtual Education Hub.